Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$29.48 +2.1%	$28.08	$23.23 ▼ $42.29	$947.25M	0.63	427,338 shs	268,741 shs
ELVN Enliven Therapeutics	$15.99 -2.5%	$18.27	$13.30 ▼ $30.03	$784.61M	1.07	259,746 shs	206,822 shs
LFCR Lifecore Biomedical	$7.00 +4.2%	$6.50	$3.68 ▼ $7.99	$259.18M	0.65	238,517 shs	1.57 million shs
XFOR X4 Pharmaceuticals	$3.39 +9.4%	$5.25	$2.67 ▼ $33.90	$19.63M	0.73	98,852 shs	202,062 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	+2.15%	-1.60%	+10.04%	+3.99%	-13.93%
ELVN Enliven Therapeutics	-2.50%	-8.00%	-12.19%	-21.15%	-33.21%
LFCR Lifecore Biomedical	+4.17%	+5.58%	+9.72%	+17.25%	+24.56%
XFOR X4 Pharmaceuticals	+9.35%	+25.09%	+1,684.21%	-72.22%	-87.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.0429 of 5 stars	3.4	0.0	3.0	4.0	0.8	2.5
ELVN Enliven Therapeutics	2.5817 of 5 stars	3.6	2.0	0.0	2.4	4.2	0.0
LFCR Lifecore Biomedical	1.1806 of 5 stars	2.3	0.0	0.0	2.0	4.2	0.6
XFOR X4 Pharmaceuticals	4.5709 of 5 stars	3.5	4.0	4.6	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.80	48.58% Upside
ELVN Enliven Therapeutics	3.20	Buy	$37.25	132.96% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	14.29% Upside
XFOR X4 Pharmaceuticals	3.00	Buy	$72.33	2,033.73% Upside

Current Analyst Ratings Breakdown

Latest LFCR, XFOR, ELVN, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/2/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $7.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/27/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
3/26/2025	XFOR X4 Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$664.28M	1.43	$10.68 per share	2.76	$5.99 per share	4.92
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A
LFCR Lifecore Biomedical	$130.31M	1.99	N/A	N/A	$0.37 per share	18.92
XFOR X4 Pharmaceuticals	$31.36M	0.63	N/A	N/A	$0.31 per share	10.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$48.15M	$1.22	12.71	4.90	N/A	14.78%	104.67%	18.38%	8/14/2025 (Estimated)
ELVN Enliven Therapeutics	-$71.58M	-$1.92	N/A	N/A	N/A	N/A	-29.46%	-27.33%	8/12/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-12.52%	-315.23%	-12.74%	8/8/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$101.17M	$2.14	N/A	N/A	N/A	N/A	-236.19%	-75.14%	8/14/2025 (Estimated)

Latest LFCR, XFOR, ELVN, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/1/2025	Q1 2025	XFOR X4 Pharmaceuticals	-$4.13	$0.04	+$4.17	$0.04	$7.03 million	$28.81 million
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million
3/25/2025	Q4 2024	XFOR X4 Pharmaceuticals	-$5.10	-$6.00	-$0.90	-$0.20	$1.07 million	$1.43 million
3/13/2025	Q4 2024	ELVN Enliven Therapeutics	-$0.53	-$0.46	+$0.07	-$0.46	N/A	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.43	0.97	0.88
ELVN Enliven Therapeutics	N/A	17.44	17.44
LFCR Lifecore Biomedical	9.21	2.32	1.21
XFOR X4 Pharmaceuticals	1.26	4.89	4.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
ELVN Enliven Therapeutics	95.08%
LFCR Lifecore Biomedical	83.36%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
ELVN Enliven Therapeutics	29.20%
LFCR Lifecore Biomedical	32.20%
XFOR X4 Pharmaceuticals	2.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	34.59 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	26.58 million	Optionable
XFOR X4 Pharmaceuticals	80	5.79 million	167.78 million	Optionable

LFCR, XFOR, ELVN, and COLL Headlines

Recent News About These Companies

X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA Congress

May 16, 2025 | nasdaq.com

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results

May 5, 2025 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Expected to Rise, HC Wainwright Analyst Says

May 4, 2025 | marketbeat.com

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...

May 2, 2025 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript

May 2, 2025 | insidermonkey.com

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4.9% - Time to Sell?

May 1, 2025 | marketbeat.com

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025 | seekingalpha.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | finance.yahoo.com

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025 | globenewswire.com

X4 Pharmaceuticals Q1 2025 Earnings Preview

April 30, 2025 | msn.com

X4 Pharmaceuticals Analyst Ratings

April 30, 2025 | benzinga.com

Earnings Preview For X4 Pharmaceuticals

April 30, 2025 | benzinga.com

X4 Pharmaceuticals (NASDAQ:XFOR) Sets New 1-Year Low - Here's Why

April 30, 2025 | marketbeat.com

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

April 30, 2025 | insidermonkey.com

X4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28

April 26, 2025 | nasdaq.com

X4 Pharmaceuticals trading halted, news pending

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals announces 1-for-30 reverse stock split

April 26, 2025 | markets.businessinsider.com

X4 Pharmaceuticals to conduct reverse stock split

April 24, 2025 | msn.com

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

April 24, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Reverse Stock Split

April 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR, XFOR, ELVN, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$29.48 +0.62 (+2.15%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$31.09 +1.61 (+5.46%)

As of 05/27/2025 07:04 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$15.99 -0.41 (-2.50%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$16.81 +0.82 (+5.12%)

As of 05/27/2025 07:33 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Lifecore Biomedical NASDAQ:LFCR

$7.00 +0.28 (+4.17%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.07 +0.07 (+1.01%)

As of 04:03 AM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

X4 Pharmaceuticals NASDAQ:XFOR

$3.39 +0.29 (+9.35%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$3.43 +0.04 (+1.18%)

As of 04:56 AM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time